Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Emergence of Linezolid-Resistant Staphylococcus aureus after Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio
Andrea Endimiani,Martha G. Blackford,Elliot C. Dasenbrook,Michael D. Reed,Saralee Bajaksouszian,Andrea M. Hujer,Andrea M. Hujer,Susan D. Rudin,Susan D. Rudin,Kristine M. Hujer,Kristine M. Hujer,Vincent Perreten,Louis B. Rice,Michael R. Jacobs,Michael W. Konstan,Robert A. Bonomo,Robert A. Bonomo +16 more
TL;DR: Genotyping by repetitive extrapalindromic PCR and pulsed-field gel electrophoresis revealed that seven of these eight LRSA strains from unique patients were genetically similar, and Emergence of LRSA is a serious concern for CF patients who undergo prolonged courses of LZD therapy.
Journal ArticleDOI
Synthesized zinc peroxide nanoparticles (ZnO 2 -NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds
TL;DR: The synthesized zinc peroxide NPs have demonstrated a competitive capability as antimicrobial, anti-elastase,Anti-keratinase, and anti-inflammatory candidates, suggesting that the ZnO2-NPs are promising metal oxides that are potentially valued for biomedical applications.
Journal ArticleDOI
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
Adrián Sousa,María Teresa Pérez-Rodríguez,Adriana Soto,Lorena Rodríguez,Antonio Pérez-Landeiro,Lucía Martínez-Lamas,Andrés Nodar,Manuel Crespo +7 more
TL;DR: Ceftazidime/avibactam shows promising results, even in monotherapy, for the treatment of patients with severe infections due to OXA-48-producing Enterobacteriaceae and limited therapeutic options.
Journal ArticleDOI
Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India.
Gururaja P. Pazhani,Swapan Kumar Niyogi,Anil Kumar Singh,Bhaswati Sen,Neelam Taneja,Manikuntala Kundu,Shinji Yamasaki,Thandavarayan Ramamurthy +7 more
TL;DR: PFGE analysis revealed clonality among strains of S. dysenteriae types 1 and 5, S. flexneri type 2a and Shigella boydii type 12 and confirmed the presence of the qnr plasmid and other genes encoding resistance to various antimicrobials.
Journal ArticleDOI
Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function
Vincent H. Tam,Peggy S. McKinnon,Ronda L. Akins,George L. Drusano,Michael J. Rybak,Michael J. Rybak +5 more
TL;DR: Current dosing recommendations may be suboptimal for monotherapy of infections due to less susceptible pathogens (e.g., those for which MICs are ≥4 mg/liter), particularly when CLCR exceeds 120 ml/min.